Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 10.80 GF Score: 70/100

Q3 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript

Nov 05, 2020 / 01:00PM GMT
Release Date Price: $5.31 (+0.19%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Adaptimmune's Third Quarter 2020 Financial Results and Business Update. (Operator Instructions). Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the conference over to your host, Adaptimmune's Investor Relations, Juli Miller. Madam, please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - Senior Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our third quarter 2020 financial results and business update. I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call, and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC. Adrian Rawcliffe, our Chief Executive Officer; and Elliot Norry, our Chief Medical Officer, are with me for the prepared portion of this call. Other members of our management team will be available for Q

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot